Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01146925 | Deferiprone for the Prevention of Contrast-Induced Acute Kidney Injury | PHASE2 | COMPLETED | 60 | — | — | Jun 1, 2010 | Jun 1, 2011 | Jun 27, 2011 | 8 | United States |
Mean paired change in a panel of acute kidney injury (AKI) biomarkers (urinary NGAL, LFABP, interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), urinary alpha GST (proximal tubular injury), Pi GST (distal tubular injury) and cystatin C; serum cystatin C) from baseline (Day 1) to peak in the deferiprone and placebo treatment groups, within 192 hours of contrast exposure
| Arm | Type | Description |
|---|---|---|
| CRMD-001-Deferiprone | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CRMD-001-Deferiprone | DRUG | CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days |
| Placebo | DRUG | 3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography |
Inclusion Criteria: 1. Age 18 or older 2. eGFR of \< 60 ml/min/1.73 m2 3. Presence of at least one additional risk factor: * Diabetes Mellitus * Age ≥ 75 years * Left Ventricular Ejection Fraction ≤ 40% Exclusion Criteria: 1. End-Stage Renal Disease 2. Recent change in serum creatinine ...